Intellia Therapeutics (NTLA) Receivables (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Receivables data on file, last reported at $9.1 million in Q1 2026.

• On a quarterly basis, Receivables fell 13.07% year-over-year to $9.1 million in Q1 2026; TTM through Mar 2026 was $9.1 million, a 13.07% decrease from a year earlier, with the FY2025 full-year figure at $9.5 million, up 11.54% from the prior year.
• Receivables for Q1 2026 stood at $9.1 million, down from $9.5 million in the prior quarter.
• Over the last five years, Receivables for NTLA reached as high as $37.5 million in Q4 2023 and fell as low as $3.6 million in Q1 2022.
• Historically, Receivables has averaged $11.6 million across 5 years, with a median of $8.9 million in 2024.
• Across the five-year window, Receivables surged 597.76% in 2023 and sank 77.26% in 2024, its largest moves.
• Year by year, Receivables stood at $5.4 million in 2022, then jumped by 597.76% to $37.5 million in 2023, then sank by 77.26% to $8.5 million in 2024, then climbed by 11.54% to $9.5 million in 2025, then slipped by 3.88% to $9.1 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $9.1 million in Q1 2026, $9.5 million in Q4 2025, and $11.0 million in Q3 2025.